how peptides actually move.
the same molecule, three legally distinct supply chains, a 285x to 1,500x price multiplier with no chemistry change. this is the map.
start at the top with the Chinese API factories. follow the lines down through the August 2024 NMPA export-only carve-out, the white-label repackaging layer, the 503A/503B compounding pharmacies, and the FDA Green List, to the three end-user populations. continue through the research hub.
the factories.
world's largest peptide CDMO build. tripled SPPS capacity in 24 months. FDA-inspected.
confirmed CDMO for Innovent's mazdutide, world's first GCG/GLP-1 dual.
made the world's first approved generic liraglutide. cost 40% below european peers.
self-claimed global #2 long-chain GLP-1 peptide capacity behind WuXi.
uses E. coli fermentation in place of solid-phase synthesis. cuts against the SPPS-dominant narrative.
named in House Select Committee letter on illicit GLP-1 manufacturing. NMPA-tolerated; blocked from the FDA Green List.
operates at the seam between NMPA tolerance and FDA enforcement. listed on B2B platforms.
third firm flagged in december 2024 GLP-1 illicit-supply letters. continuing operations without NMPA enforcement.
produces Wegovy + Ozempic API in-house. zero meaningful Chinese API exposure for branded supply.
tirzepatide produced in-house. Chinese tirzepatide patent doesn't expire until january 2036.
the distribution layer.
Chinese GMP plants can manufacture APIs not approved for human use in China, against the buyer's specifications.
where unbranded API gets sourced. listings without NMPA marketing-authorization numbers.
lyophilize, vial, label, drop-ship under whatever brand the storefront has chosen.
whitelist regime: only manufacturers FDA has inspected can ship without DWPE.
Novo paid $11B for three Catalent fill-finish sites in feb 2024. captive supply.
the retail layer.
FDA pierces RUO labeling via §201(g)(1) intent doctrine. 50+ warning letters Sep 2025 alone.
shortage exception ended feb 2025. Empower hit FDA WL April 2025 (sema 79.9% potency).
Hims fell 25% in a session after Feb 2025 sema delisting. now selling branded Wegovy via Novo.
Novo's 74% rebate gap means realized US net price is roughly half of WAC.
Novo's direct-to-consumer cash channel. 2027 unified list price drops to $675/mo.
the end user.
Turnock 2024 netnography: entry often follows a negative healthcare-provider encounter.
Hims posted $1.48B 2024 revenue, +69% YoY, mostly riding the compounded-GLP-1 wave.
12% of US adults currently on a GLP-1. 76% got the prescription from a doctor. 54% find it difficult to afford.
browse every research destination.
return to the shared catalog for rankings, suppliers, reports, outcome guides, journal, and briefs. open research →
one email a month on what moved in peptide research. trial readouts, regulatory shifts, market structure. the dispatch is separate from these maps and articles.